| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | 0.16 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |